Trials / Completed
CompletedNCT00693056
Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)
A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Rexahn Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this Phase IIa trial is to determine the effective doses and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ED receiving RX-10100 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo (w/o API) |
| DRUG | RX-10100 5mg | 5 mg/dose of RX-10100 |
| DRUG | RX-10100 10mg | 10 mg/dose of RX-10100 |
| DRUG | RX-10100 15mg | 15 mg/dose of RX-10100 |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2009-03-01
- Completion
- 2009-05-01
- First posted
- 2008-06-06
- Last updated
- 2009-05-05
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00693056. Inclusion in this directory is not an endorsement.